Stock Events

Bristol-Myers Squibb 

$848
14
+$8+0.95% Tuesday 14:42

Statistics

Day High
848
Day Low
848
52W High
1,255.01
52W Low
700
Volume
1
Avg. Volume
3
Mkt Cap
155.21B
P/E Ratio
0
Dividend Yield
0.24%
Dividend
2

Upcoming

Dividends

0.24%Dividend Yield
Mar 24
$0.5
Dec 23
$0.5
Sep 23
$0.5
Jun 23
$0.5
Mar 23
$0.5

Earnings

25AprExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
1.53
1.7
1.88
2.05
Expected EPS
1.65
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BMYMP. It's not an investment recommendation.

About

Pharmaceuticals: Major
Health Technology
Manufacturing
Pharmaceutical Preparation Manufacturing
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Show more...
CEO
Dr. Giovanni Caforio M.D.
Employees
32200
Country
United States
ISIN
US1101222073

Listings